MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
China Pharma Holdings Market Cap 2011-2026 | CPHI
As of March 04, 2026 China Pharma Holdings has a market cap of $ 9.61 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap China Pharma Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.54 M | 1.25 M | 368 K | 2.21 M | 30.9 M | 18.3 M | 12.6 M | 14.8 M | 10.9 M | 6.1 M | 13.1 M | 18.7 M | 10.9 M | 33 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33 M | 368 K | 12.7 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
142 M | $ 1.07 | -0.47 % | $ 115 M |  Canada |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Harrow Health
HROW
|
1.93 B | $ 38.95 | -27.32 % | $ 1.43 B | USA |
 |
Cronos Group
CRON
|
3.63 B | $ 2.62 | -0.57 % | $ 1.36 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
82.8 M | - | - | $ 33.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 4.5 | -7.02 % | $ 63.3 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
915 M | $ 3.52 | -5.26 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Organogenesis Holdings
ORGO
|
415 M | $ 2.86 | -4.67 % | $ 377 M | USA |
 |
Emergent BioSolutions
EBS
|
139 M | $ 8.87 | -1.33 % | $ 454 M | USA |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
66.1 M | $ 11.92 | 1.24 % | $ 847 M | USA |
 |
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
35.5 M | $ 0.9 | 0.37 % | $ 21 M | USA |
 |
Evolus
EOLS
|
271 M | $ 4.21 | -1.86 % | $ 261 M | USA |
 |
Bausch Health Companies
BHC
|
3.38 B | $ 5.77 | -3.11 % | $ 2.11 B | Canada |
 |
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
382 M | $ 1.38 | -3.17 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
1.96 B | $ 11.38 | -7.97 % | $ 1.58 B | USA |
 |
Sundial Growers
SNDL
|
889 K | $ 1.53 | 0.33 % | $ 3.37 M | Canada |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 22.06 | 3.67 % | $ 1.02 B | USA |
 |
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
162 M | $ 4.67 | -3.51 % | $ 141 M | USA |
 |
SCYNEXIS
SCYX
|
70.3 M | $ 0.73 | -2.19 % | $ 34.9 M | USA |
 |
Solid Biosciences
SLDB
|
226 M | $ 5.99 | -3.47 % | $ 244 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 2.76 | -2.66 % | $ 3.43 M | USA |
 |
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
23.9 M | $ 2.26 | 1.0 % | $ 23.6 M | USA |
 |
Tilray
TLRY
|
1.19 B | $ 7.37 | -2.97 % | $ 4.55 B | Canada |
 |
Veru
VERU
|
108 M | $ 2.54 | -3.05 % | $ 343 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 15.09 | -3.89 % | $ 18.1 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |
 |
cbdMD
YCBD
|
1.68 M | $ 0.79 | -2.48 % | $ 3.41 M | USA |